Articles From: BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting to Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions


RESEARCH TRIANGLE PARK, N.C., Sept.
Sign-up for BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021635-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/12/11G021635/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - September 15, 2014) - Biodel Inc. (NASDAQ: BIOD) will present data from human and animal studies with its ultra-rapid-acting prandial insulin product candidates during the 50 th Annual Meeting of the European Association for the Study of Diabetes (EASD) being held in Vienna, Austria from September 15-19, 2014.
Sign-up for Biodel Announces Data Presentations at the 50th Annual Meeting of the EASD investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020442-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/25/11G020442/Biodel_Life_Delivered_600dpi-1189716966656.jpg DANBURY, CT--(Marketwired - August 25, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that Gary G.
Sign-up for Biodel Appoints Gary G. Gemignani as Chief Financial Officer investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019045-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/7/25/11G019045/Biodel-Life-Delivered_000-1401197537254.jpg DANBURY, CT--(Marketwired - July 28, 2014) - Biodel Inc. (NASDAQ: BIOD) today announced that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor.
Sign-up for Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019790-001&sourceType=1 DANBURY, CT--(Marketwired - August 11, 2014) - Biodel Inc. (NASDAQ: BIOD) today reported financial results for the third fiscal quarter ended June 30, 2014.
Sign-up for Biodel Reports Third Quarter Fiscal Year 2014 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019553-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/4/11G019553/biodel-362213870360.jpg DANBURY, CT--(Marketwired - August 06, 2014) - Biodel Inc. (NASDAQ: BIOD) management will be presenting an overview of the Company's technologies, development programs, and outlook at the Wedbush PacGrow Life Sciences Management Access Conference being held at Le Parker Meridien from August 12-13, 2014.
Sign-up for Biodel to Present at the Wedbush PacGrow Life Sciences Management Access Conference investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019552-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/4/11G019552/biodel-1200626067260.jpg DANBURY, CT--(Marketwired - August 05, 2014) - Biodel Inc. (NASDAQ: BIOD) will issue its third quarter fiscal year 2014 financial results on August 11, 2014.
Sign-up for Biodel to Report Third Quarter Fiscal Year 2014 Financial Results on August 11, 2014 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G019770-001&sourceType=1 DANBURY, CT--(Marketwired - August 11, 2014) - Biodel Inc. (NASDAQ: BIOD) announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to Humalog ® Mix 75/25 and Humulin ® R U-500 in patients with type 2 diabetes with moderate insulin resistance who use between 50 and 200 units of insulin per day.
Sign-up for Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior Glucose Control Following Standardized Meals Compared to Marketed Insulins in a Phase 2 Clinical Trial in Patients With Type 2 Diabetes investment picks
BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals RALEIGH, N.C. , Aug.
Sign-up for BioDelivery Sciences Announces BEMA Buprenorphine NDA Submission on Track following Pre-NDA Meeting with FDA investment picks
RALEIGH, N.C. , July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J.
Sign-up for BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors investment picks
BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 2nd Positive Phase 3 BEMA Buprenorphine clinical trial in chronic pain leads to NDA submission targeted for year-end or early 2015 Enrollment for Clonidine Topical Gel for Painful Diabetic Neuropathy Phase 3 trial expected to complete by year-end; Top-line results anticipated by end of 1Q15 Company earns $10 million milestone from Endo on BEMA Buprenorphine Phase 3 data lock and had $88 million in cash as of July 7 BDSI will host an investor and analyst luncheon on September 5 in New York City RALEIGH, N.C. , Aug.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2014 Financials investment picks
NEW YORK (MarketWatch) -- Shares of BioDelivery Sciences International (BDSI) are rallying 22% in active premarket trade after the company and its partner, Endo Pharmaceuticals, said a late-stage trial of its severe pain treatment met its primary efficacy endpoint.
Sign-up for BioDelivery Sciences rallies premarket on positive trial data investment picks
RALEIGH, N.C. , Sept.
Sign-up for BioDelivery Sciences to Present at the Morgan Stanley Global Healthcare Conference investment picks
September 4th ceremony celebrates 2014 accomplishments including FDA approval and anticipated commercial launch of BUNAVAIL RALEIGH, N.C. , Sept.
Sign-up for BioDelivery Sciences to Ring The NASDAQ Stock Market Opening Bell investment picks
2014/8/4
FREDERICK, Md.
Sign-up for BioElectronics President Letter to Shareholders investment picks
2014/9/25
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147219&ProfileId=051205&sourceType=1 VIRGINIA BEACH, VA --
Sign-up for BioForce Nanosciences Holdings, Inc. (BFNH) Acquires Two Entities Related to Kale Agriculture investment picks
2014/9/19
DENVER , Sept.
Sign-up for BioFuel Announces Rights Offering investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential violations of securities laws and breach of fiduciary duty claims against the Board of Directors of BioFuel Energy Corp.
Sign-up for BIOFUEL ENERGY INVESTOR ALERT - Andrews & Springer LLC Is Investigating BioFuel Energy Corp. For Possible Violations of Securities Laws and Breaches of Fiduciary Duty - BIOF investment picks
2014/7/2
DENVER , July 2, 2014 /PRNewswire/ -- BIOFUEL ENERGY CORP.
Sign-up for BioFuel Energy Receives Favorable NASDAQ Listing Determination Pending Completion of JBGL Transaction investment picks
2014/9/23
DENVER , Sept.
Sign-up for BioFuel Makes Announcement Regarding Rights Offering investment picks
Biofuels Power Corporation (OTCBB:BFLS) announced today that it has signed a letter of intent with ThyssenKrupp Industrial Solutions (Africa) (Pty) Ltd (“ThyssenKrupp”) and Liberty GTL, Inc. (“Liberty”) to build a small-scale gas-to-liquid demonstration facility in Houston, Texas (“GTL Pilot Plant”). The parties have established a non-binding target date to complete installation and commissioning of the GTL Pilot Plant on or before December 31, 2014.
Sign-up for Biofuels Power Corp Announces Plans to Build Gas-to-Liquids Pilot Plant in Houston, Texas investment picks
U.S. agencies including the EPA, Dept.
Sign-up for Biogas Opportunities Road Map Report from U.S. Government Points to Huge Opportunity for Bluesphere in U.S. Market investment picks
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country.
Sign-up for Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS) investment picks
Biogen Idec (NASDAQ: BIIB) will present more than 90 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for multiple sclerosis (MS), as well as the company’s programs to address unmet needs in patient management, at the sixth Triennial Joint Meeting of ACTRIMS and ECTRIMS in Boston, September 10 – 13, 2014.
Sign-up for Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care investment picks
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will participate in a panel at the Citi 9 th Annual Biotech Conference.
Sign-up for Biogen Idec in Panel at the Citi 9th Annual Biotech Conference investment picks
Biogen Idec (NASDAQ:BIIB) has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive year, one of only two biotech companies included.
Sign-up for Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index investment picks
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014.
Sign-up for Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting to Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices